Overview

Study to Evaluate Pharmacokinetics of Prototype Modified-Release Formulations Of Apremilast in Healthy Men

Status:
Completed
Trial end date:
2014-09-11
Target enrollment:
Participant gender:
Summary
This study will assess up to 12 different oral formulations of apremilast to determine how much apremilast is absorbed by the body compared to a reference formulation.
Phase:
Phase 1
Details
Lead Sponsor:
Amgen
Celgene Corporation
Treatments:
Apremilast
Thalidomide